Thrombectomy for Stroke in the Public Health Care System of Brazil
Source: View publication →
The RESILIENT trial demonstrated that mechanical thrombectomy combined with standard care significantly improves functional outcomes at 90 days for patients with acute ischemic stroke due to large-vessel occlusion in a resource-limited public healthcare setting compared to standard care alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The RESILIENT trial provided critical, real-world evidence that mechanical thrombectomy is safe, feasible, and highly efficacious for acute ischemic stroke in resource-limited public healthcare systems. By proving that the profound benefits seen in high-income country trials could be successfully replicated in a developing nation despite systemic challenges (e.g., transport delays, lack of specialized stroke centers), this trial catalyzed the official adoption and public funding of mechanical thrombectomy within the Brazilian Sistema Único de Saúde (SUS) and served as a blueprint for implementing advanced stroke networks in other LMICs.
Historical Context
Following a series of landmark randomized trials published between 2014 and 2015 (such as MR CLEAN, ESCAPE, and EXTEND-IA) that established mechanical thrombectomy as the gold standard for large-vessel occlusion stroke, adoption in developing nations lagged severely due to high device costs and infrastructural deficits. In response, Brazilian stroke experts and international collaborators designed the RESILIENT trial to explicitly test the therapy in a real-world, under-resourced public health system. Its landmark success eventually led the Brazilian Ministry of Health to formally authorize reimbursement for thrombectomy nationwide in late 2023.
Guided Discussion
High-yield insights from every perspective
In acute ischemic stroke, what defines a 'large-vessel occlusion' (LVO), and physiologically, why is mechanical thrombectomy more effective than intravenous thrombolysis alone for these specific lesions?
Key Response
LVOs typically involve the internal carotid artery (ICA) or the M1 segment of the middle cerebral artery (MCA). IV thrombolysis (alteplase or tenecteplase) relies on enzymatic clot dissolution, which is often insufficient for the large clot burden in LVOs due to limited surface area exposure and poor flow dynamics. Mechanical thrombectomy directly removes the physical obstruction, restoring perfusion much faster and more reliably.
When evaluating a patient in the ED for potential enrollment in a thrombectomy protocol similar to the RESILIENT trial, what specific neuroimaging criteria and clinical scoring tools are required to determine eligibility?
Key Response
Residents must know how to select patients appropriately. This typically involves a non-contrast CT head to rule out hemorrhage and assess the ASPECTS score (usually greater than 5 indicates a favorable tissue profile), followed by CT angiography to confirm an anterior circulation LVO (ICA or M1). Clinically, the NIHSS is used to quantify stroke severity, and the patient's baseline modified Rankin Scale (mRS) should ideally be 0-1 to ensure they had good pre-morbid functional status.
The RESILIENT trial was conducted in a resource-limited public healthcare network. How does the 'drip-and-ship' versus 'mothership' routing paradigm impact outcomes in such networks, and how did this trial account for transfer delays?
Key Response
Fellows need to understand stroke systems of care. In resource-limited settings, patients often present to primary centers (drip-and-ship) rather than comprehensive stroke centers (mothership), causing significant delays in puncture times. The RESILIENT trial demonstrated that despite these real-world systemic delays and less sophisticated transfer logistics typical of a public health system, the treatment effect of thrombectomy remained highly significant, highlighting the robustness of the intervention even outside of idealized, high-income 'mothership' paradigms.
Given the positive results of the RESILIENT trial, how should stroke network directors in low-to-middle-income countries balance the high upfront capital and personnel costs of establishing neurointerventional suites against the long-term public health savings of reduced stroke morbidity?
Key Response
Attendings and medical directors must weigh system-level costs. While the initial investment for angiosuites, devices, and specialized neurointerventionalists is massive, the RESILIENT trial provides the crucial evidence that reducing the 90-day severe disability burden (mRS 4-6) significantly cuts long-term nursing, rehabilitation, and disability costs. This justifies the upfront expenditure to health ministries by demonstrating a favorable cost-effectiveness ratio even in constrained economies.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The RESILIENT trial utilized a group-sequential design and was stopped early for efficacy. What are the statistical risks of stopping a trial early due to interim efficacy analyses, and how did the investigators mitigate the potential for overestimating the treatment effect?
Key Response
Stopping early for efficacy can sometimes lead to an exaggerated treatment effect estimate, often referred to as a random high. Investigators mitigate this by using strict pre-specified alpha-spending functions (e.g., O'Brien-Fleming boundaries) that require overwhelming statistical significance at early interim analyses to declare efficacy. However, researchers must critically evaluate if the truncated sample size compromises the statistical power to detect important secondary outcomes or safety signals, such as symptomatic intracranial hemorrhage rates.
As a peer reviewer, how would you evaluate the pragmatic elements of the RESILIENT trial's protocol, specifically regarding the lack of advanced perfusion imaging for patient selection, and does this threaten the validity of its findings?
Key Response
Journal editors scrutinize how trial design impacts real-world applicability. Many pivotal trials (like DAWN and DEFUSE-3) mandated advanced perfusion imaging to select late-window patients. RESILIENT deliberately used basic non-contrast CT and CTA to reflect the reality of a developing public health system. Far from being a threat to validity, this pragmatic choice is the study's greatest strength, as it proves that advanced imaging is not an absolute prerequisite for achieving significant functional benefits with thrombectomy in the early window, drastically increasing external validity for global settings.
How does the RESILIENT trial inform global stroke management guidelines (e.g., WSO or AHA/ASA) specifically regarding the minimum required imaging modalities and structural prerequisites for establishing level 1 recommendation thrombectomy protocols in low-resource environments?
Key Response
AHA/ASA guidelines already give mechanical thrombectomy a Class I, Level of Evidence A recommendation. However, earlier pivotal trials primarily represented high-resource settings using advanced imaging. RESILIENT provides Level A evidence that standard CT and CTA alone are sufficient for patient selection in the early window. This prompts guidelines to explicitly endorse the broader rollout of thrombectomy services in low-to-middle-income countries without the prerequisite of advanced perfusion software, thereby democratizing access to this life-saving therapy while maintaining a high strength of recommendation.
Clinical Landscape
Noteworthy Related Trials
MR CLEAN
Tested
Endovascular thrombectomy plus usual care
Population
Patients with acute ischemic stroke caused by proximal anterior circulation occlusion
Comparator
Usual care alone (including IV tPA)
Endpoint
Modified Rankin Scale score at 90 days
ESCAPE
Tested
Rapid endovascular thrombectomy
Population
Acute ischemic stroke patients with proximal anterior circulation occlusion and small infarct core
Comparator
Standard medical care
Endpoint
Modified Rankin Scale score at 90 days
DAWN
Tested
Endovascular thrombectomy plus standard medical care
Population
Patients with acute ischemic stroke presenting 6 to 24 hours after last known well with clinical-core mismatch
Comparator
Standard medical care alone
Endpoint
Utility-weighted modified Rankin scale score at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis